From: Re-irradiation of anaplastic meningioma: higher dose and concomitant Bevacizumab may improve progression-free survival
Variable
HR (CI95%)
P
RT > 50gy
0.3 (0.045-0.8)
0.03
2ND surgery (yes)
0.39 (0.12–1.2)
0.109
Bevacizumab concomittemt (yes)
0.27 (0.06–1.27)
0.1
CDKN2A homozygous deletion (yes)
11 (3.1–38.4)
< 0.001